Constellation Pharmaceuticals Inc.

21.47-0.3700-1.69%Vol 166.53K1Y Perf -37.97%
Apr 13th, 2021 14:23 DELAYED
BID21.47 ASK21.51
Open21.96 Previous Close21.84
Pre-Market- After-Market-
 - -%  - -
Target Price
46.78 
Analyst Rating
Strong Buy 1.33
Potential %
117.58 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap1.03B 
Earnings Rating
Neutral
Price Range Ratio 52W %
13.19 
Earnings Date
5th May 2021

Today's Price Range

21.4522.81

52W Range

17.0050.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.58%
1 Month
-27.27%
3 Months
-25.18%
6 Months
-8.31%
1 Year
-37.97%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CNST21.47-0.3700-1.69
AAPL134.243.00002.29
GOOG2 263.408.61000.38
MSFT257.922.01000.79
XOM55.700.20000.36
WFC39.85-0.9200-2.26
JNJ158.87-2.7700-1.71
FB312.210.67000.22
GE13.46-0.1300-0.96
JPM154.41-1.5400-0.99
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.74-0.79-6.76
Q03 2020-0.71-0.710.00
Q02 2020-0.64-0.70-9.38
Q01 2020-0.64-0.614.69
Q04 2019-0.67-0.69-2.99
Q03 2019-0.81-0.82-1.23
Q02 2019-0.80-0.800.00
Q01 2019-0.80-0.756.25
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.8075.16Positive
6/2021 QR-0.8675.14Positive
12/2021 FY-3.32--
12/2022 FY-3.55--
Next Report Date5th May 2021
Estimated EPS Next Report-0.80
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume166.53K
Shares Outstanding47.86M
Trades Count2.35K
Dollar Volume31.44M
Avg. Volume459.30K
Avg. Weekly Volume295.43K
Avg. Monthly Volume424.26K
Avg. Quarterly Volume458.03K

Constellation Pharmaceuticals Inc. (NASDAQ: CNST) stock closed at 21.84 per share at the end of the most recent trading day (a -2.93% change compared to the prior day closing price) with a volume of 408.50K shares and market capitalization of 1.03B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 154 people. Constellation Pharmaceuticals Inc. CEO is Jigar Raythatha.

The one-year performance of Constellation Pharmaceuticals Inc. stock is -37.97%, while year-to-date (YTD) performance is -24.17%. CNST stock has a five-year performance of %. Its 52-week range is between 17 and 50.9, which gives CNST stock a 52-week price range ratio of 13.19%

Constellation Pharmaceuticals Inc. currently has a PE ratio of -8.10, a price-to-book (PB) ratio of 2.66, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -30.05%, a ROC of -39.56% and a ROE of -33.77%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Constellation Pharmaceuticals Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.80 for the next earnings report. Constellation Pharmaceuticals Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Constellation Pharmaceuticals Inc. is Strong Buy (1.33), with a target price of $46.78, which is +117.58% compared to the current price. The earnings rating for Constellation Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Constellation Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Constellation Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 21.40, ATR14 : 2.45, CCI20 : -97.05, Chaikin Money Flow : -0.29, MACD : -2.30, Money Flow Index : 40.84, ROC : -6.75, RSI : 38.00, STOCH (14,3) : 5.16, STOCH RSI : 0.81, UO : 29.48, Williams %R : -94.84), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Constellation Pharmaceuticals Inc. in the last 12-months were: Adrian Senderowicz (Option Excercise at a value of $51 557), Adrian Senderowicz (Sold 9 357 shares of value $469 488 ), Emma Reeve (Option Excercise at a value of $422 654), Emma Reeve (Sold 48 877 shares of value $2 162 876 ), James E. Audia (Sold 13 600 shares of value $644 221 ), Jigar Raythatha (Option Excercise at a value of $50 885), Jigar Raythatha (Sold 9 235 shares of value $463 281 ), Karen Valentine (Option Excercise at a value of $464 740), Karen Valentine (Sold 41 000 shares of value $1 502 355 ), Mark A. Goldsmith (Option Excercise at a value of $78 005), Mark A. Goldsmith (Sold 23 353 shares of value $1 015 661 ), Patrick Trojer (Option Excercise at a value of $70 385), Patrick Trojer (Sold 10 000 shares of value $451 553 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (77.78 %)
7 (77.78 %)
7 (77.78 %)
Moderate Buy
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
Hold
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.33
Strong Buy
1.33

Constellation Pharmaceuticals Inc.

Constellation Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead products include CPI-0610, which is a small molecule designed to promote anti-tumor activity by specifically inhibiting the function of BET proteins, which normally enhance target gene expression, and CPI-1205 which is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. It operates in the segment of the development of novel therapeutics in the field of epigenetics.

CEO: Jigar Raythatha

Telephone: +1 617 714-0555

Address: 215 First Street, Cambridge 02142, MA, US

Number of employees: 154

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

47%53%

Bearish Bullish

53%47%

Bearish Bullish

59%41%

News

Stocktwits